CSL Executive and Leadership Team

Gordon Naylor, the Interim Chief Executive Officer & Managing Director at CSL, directs the company's overarching strategy and global operations. Naylor guides CSL's mission to save lives through its portfolio of hemophilia and immune deficiency treatments, influenza vaccines, and therapies for iron deficiency and nephrology. This leadership role involves steering the organization towards continued technological advancement and market expansion. Naylor ensures the effective execution of CSL's long-term vision, fostering innovation across all business units. The focus remains on leveraging cutting-edge technologies to deliver essential medicines worldwide. Gordon Naylor drives the strategic direction for CSL's global presence, ensuring operational excellence and sustainable growth across all therapeutic areas.

Ken Lim, the Chief Financial Officer at CSL, oversees all financial operations and strategic fiscal planning for the global biotechnology company. Lim manages the financial health of CSL, ensuring robust capital allocation for its lifesaving medicines, including treatments for hemophilia, immune deficiencies, influenza vaccines, and therapies in iron deficiency and nephrology. This executive function involves driving financial performance and supporting the company's commitment to using the latest technologies to save lives. Ken Lim directs treasury, accounting, and financial reporting, providing critical insights for executive decision-making. The Chief Financial Officer ensures compliance with global financial regulations and optimizes investment strategies to fuel research and development initiatives. Lim's leadership guarantees fiscal discipline and supports CSL's long-term growth objectives.

Emiliano Chiaramonte, the Chief Financial Officer, LATAM (South) at CSL, manages financial operations and strategic fiscal planning for the South Latin America region. Chiaramonte ensures the financial viability and growth of CSL's operations within this key territory, supporting the delivery of lifesaving medicines and therapies. This executive role involves optimizing financial resources to advance CSL's mission of saving lives through technological innovation. Emiliano Chiaramonte directs regional financial reporting, budgeting, and forecasting, providing essential data for strategic decision-making. The Chief Financial Officer, LATAM (South) ensures compliance with local financial regulations and drives efficiency across all regional business units. Chiaramonte's financial acumen supports CSL's expansion and commitment to patient care in South America.

Jody Long, the Administrative Advisor To Chief Financial Officer at CSL, provides essential support and strategic counsel to the Chief Financial Officer. Long facilitates the efficient operation of the finance department, ensuring seamless execution of financial strategies for CSL's global biotechnology operations. This advisory role is key to supporting the company's mission of saving lives through its diverse portfolio of medicines and therapies. Jody Long assists in coordinating financial planning, analysis, and reporting activities, contributing to informed decision-making. The Administrative Advisor To Chief Financial Officer enhances operational effectiveness within the finance function, ensuring alignment with CSL's overarching business objectives. Long's support enables the Chief Financial Officer to drive financial performance and strategic growth.

Hamza Shanaa, the Manager Chief Marketing Officer Quality at CSL, ensures the highest standards of quality are integrated into marketing strategies and execution. Shanaa's role focuses on maintaining the integrity and effectiveness of CSL's marketing initiatives, aligning them with the company's mission to save lives through advanced biotechnology. This critical function supports the delivery of lifesaving medicines and vaccines by ensuring all promotional activities meet stringent quality benchmarks. Hamza Shanaa collaborates with marketing teams to uphold compliance and enhance brand reputation across global markets. The Manager Chief Marketing Officer Quality drives process improvements within marketing operations, guaranteeing adherence to regulatory requirements and best practices. Shanaa's oversight contributes to the consistent delivery of CSL's therapeutic solutions.

Amanda Taylor, the Chief Marketing Officer, Campaign & Manager (Americas) at CSL, spearheads marketing campaigns and strategic initiatives across the Americas region. Taylor directs the development and execution of impactful marketing programs for CSL's portfolio of lifesaving medicines, including treatments for hemophilia, immune deficiencies, influenza vaccines, and therapies for iron deficiency and nephrology. This leadership position involves understanding regional market dynamics to effectively communicate CSL's promise of saving lives through cutting-edge technology. Amanda Taylor oversees campaign performance, ensuring alignment with corporate objectives and driving market penetration within the Americas. The Chief Marketing Officer, Campaign & Manager (Americas) fosters strong relationships with healthcare providers and patient communities. Taylor's focus is on enhancing brand visibility and patient access to CSL's vital therapies.

Ruby Eappen, the Global Quality Manager, Supplier & Chief Marketing Officer at CSL, integrates quality management principles across supplier relationships and marketing functions. Eappen ensures that CSL's lifesaving medicines and therapies meet the highest global quality standards, from sourcing to patient delivery. This dual-focused role supports CSL's commitment to saving lives by maintaining product integrity and effective market communication. Ruby Eappen oversees supplier quality assurance programs and directs marketing quality initiatives, ensuring compliance and operational excellence. The Global Quality Manager, Supplier & Chief Marketing Officer drives continuous improvement in quality systems and marketing strategies. Eappen's leadership guarantees that CSL's products and communications consistently reflect the company's dedication to innovation and patient well-being.

Candice Nieves, the Manager Chief Marketing Officer Quality at CSL, upholds rigorous quality standards within the company's marketing operations. Nieves ensures that all marketing campaigns and communications for CSL's portfolio of lifesaving medicines adhere to strict quality and regulatory guidelines. This role is crucial for maintaining CSL's reputation and ensuring the accurate representation of its therapies, including those for hemophilia, immune deficiencies, influenza vaccines, and iron deficiency and nephrology. Candice Nieves collaborates with cross-functional teams to implement quality control measures throughout the marketing lifecycle. The Manager Chief Marketing Officer Quality drives adherence to best practices, safeguarding CSL's commitment to saving lives through reliable and innovative treatments. Nieves's focus is on enhancing the quality and impact of CSL's global marketing efforts.

Phyllis Post, the Vice President and Chief Information Officer, CSL Behring, Seqirus and Vifor I & T at CSL, directs the information technology strategy and infrastructure across key CSL divisions. Post oversees the implementation of advanced technological solutions that support the development and delivery of lifesaving medicines, including treatments for hemophilia, immune deficiencies, influenza vaccines, and therapies for iron deficiency and nephrology. This executive leadership role is vital for leveraging technology to advance CSL's promise of saving lives. Phyllis Post ensures robust cybersecurity measures and drives digital transformation initiatives to enhance operational efficiency and innovation. The Vice President and Chief Information Officer, CSL Behring, Seqirus and Vifor I & T champions the integration of cutting-edge IT systems to support global research and commercial operations. Post's strategic vision strengthens CSL's technological foundation.

Henry Mezzanotte, the Executive Vice President & Head Chief Medical Officer, Research Development at CSL, leads the company's critical research and development initiatives. Mezzanotte guides the scientific direction for CSL's portfolio of lifesaving medicines, focusing on innovation in areas such as hemophilia, immune deficiencies, influenza vaccines, and therapies for iron deficiency and nephrology. This senior medical leadership role is central to CSL's commitment to saving lives through the latest scientific advancements and technologies. Henry Mezzanotte oversees clinical trials, drug discovery, and regulatory affairs, ensuring the development of safe and effective therapies. The Executive Vice President & Head Chief Medical Officer, Research Development drives the scientific strategy to address unmet medical needs globally. Mezzanotte's expertise accelerates the translation of research into life-changing treatments.